CGB3
EstablishedBeta-hCG is a tumor marker for germ cell tumors and gestational trophoblastic disease, paired with AFP for staging.
Beta-hCG is best known as the pregnancy hormone, but outside of pregnancy, high levels can signal certain tumors, especially of the testis, ovary, or placenta. Doctors track it closely during treatment to make sure therapy is working.
CGB3 encodes a subunit of human chorionic gonadotropin (beta-hCG), a hormone produced by placental tissue during pregnancy and also by certain tumors, particularly germ cell tumors and gestational trophoblastic disease.
Elevated beta-hCG outside of pregnancy is a core tumor marker for gestational trophoblastic disease (molar pregnancy, choriocarcinoma) and germ cell tumors of the testis and ovary, where it is used alongside AFP for combined staging and monitoring.
Measured via serum immunoassay; serial levels are tracked during and after chemotherapy to confirm treatment response, with an expected log-linear decline defining adequate response in gestational trophoblastic disease surveillance protocols.
Combined AFP plus beta-hCG monitoring is standard for germ cell tumor staging and surveillance; failure of beta-hCG to decline as expected during chemotherapy for gestational trophoblastic disease prompts treatment regimen changes.
Serial monitoring confirms chemotherapy response; failure to decline as expected signals treatment resistance.
- American Cancer Society. Tumor Markers for Germ Cell Tumors.
- ASCO. (2020). Recommendations for Tumor Markers in Gastrointestinal and Germ Cell Cancers.